NARANHAY is an advanced antimicrobial biotechnology company developing proprietary, localized formulations designed to target pathogenic biofilms and microbial drivers of chronic inflammation.

The company’s platform is built around a mechanism-focused R&D approach that enables early biological risk reduction through localized intervention, avoiding systemic exposure. This architecture is designed to support regulatory scalability and flexible deployment across multiple product categories.

Initial development programs focus on gingival inflammation associated with Porphyromonas gingivalis, a key pathogen linked to oral-systemic inflammatory pathways, as well as antimicrobial resistance contexts, including Staphylococcus aureus (MRSA).

NARANHAY’s technology is designed for multi-segment application across oral care, preventive health, hygiene, and medical device–adjacent use cases, supporting both consumer and clinical pathways.